Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-02-28
DOI
10.3389/fonc.2020.00268
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
- (2019) Houda Bahig et al. BMC CANCER
- Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
- (2019) Arielle Elkrief et al. OncoImmunology
- Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
- (2019) Michael Platten et al. NATURE REVIEWS DRUG DISCOVERY
- Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
- (2019) Neil H. Segal et al. EUROPEAN JOURNAL OF CANCER
- Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
- (2019) Luca Cassetta et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
- (2019) Jacob H. Rasmussen et al. BRITISH JOURNAL OF CANCER
- The Intersection between Tumor Angiogenesis and Immune Suppression
- (2019) Osama E. Rahma et al. CLINICAL CANCER RESEARCH
- Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- (2019) Danny Rischin et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
- (2019) Sha Zhao et al. LUNG CANCER
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer
- (2019) Jill M. Brooks et al. CLINICAL CANCER RESEARCH
- Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
- (2019) Andrew Georgiadis et al. CLINICAL CANCER RESEARCH
- APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
- (2019) Daniel L. Faden et al. ORAL ONCOLOGY
- Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
- (2019) Joris B.W. Elbers et al. RADIOTHERAPY AND ONCOLOGY
- Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
- (2019) Lei Wu et al. Cancer Immunology Research
- STAT1 inhibits T‐cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma
- (2019) Nathan Ryan et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
- (2018) Robert D. Leone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients
- (2018) Zhuqing Liu et al. CLINICAL CANCER RESEARCH
- Specific blockade CD73 alters the ‘exhausted' phenotype of T cells in head and neck squamous cell carcinoma
- (2018) Wei-Wei Deng et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer
- (2018) Taylor T. Chrisikos et al. MOLECULAR IMMUNOLOGY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
- (2018) Robert L. Ferris et al. ORAL ONCOLOGY
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
- (2018) Maarten Versteven et al. Frontiers in Immunology
- IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy
- (2018) James C. Chen et al. Cell Systems
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients
- (2018) Ryo Kato et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Human papilloma virus specific immunogenicity and dysfunction of CD8+ T cells in head and neck cancer
- (2018) Sri Krishna et al. CANCER RESEARCH
- Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells
- (2018) Yukiyoshi Mita et al. INTERNATIONAL IMMUNOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- (2018) K. G. Paulson et al. Nature Communications
- Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade
- (2018) Deepak Mittal et al. Cancer Discovery
- Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy
- (2018) Steven F. Gameiro et al. OncoImmunology
- Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
- (2018) Y -P Chen et al. ANNALS OF ONCOLOGY
- JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer
- (2018) Yao Yu et al. Future Oncology
- Human papillomavirus and the landscape of secondary genetic alterations in oral cancers
- (2018) Maura L. Gillison et al. GENOME RESEARCH
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- The metabolite BH4 controls T cell proliferation in autoimmunity and cancer
- (2018) Shane J. F. Cronin et al. NATURE
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma
- (2017) Daniel L. Faden et al. ORAL ONCOLOGY
- Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients
- (2017) Richard Linedale et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
- (2017) Melanie Mediavilla-Varela et al. NEOPLASIA
- Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study
- (2017) Salvinia Mletzko et al. OncoImmunology
- Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
- (2017) Susanne M. Steggerda et al. Journal for ImmunoTherapy of Cancer
- Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion
- (2017) Lee A. Albacker et al. PLoS One
- An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma
- (2016) Hongzhi Quan et al. INTERNATIONAL JOURNAL OF CANCER
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment
- (2016) Koichi Sakakura et al. LABORATORY INVESTIGATION
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells
- (2016) Fernando Concha-Benavente et al. ORAL ONCOLOGY
- Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma
- (2016) Yuta Kondo et al. ORAL ONCOLOGY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages
- (2016) Hideyuki Takahashi et al. Oncotarget
- CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
- (2016) Melanie Straub et al. Oncotarget
- Microsatellite alteration in head and neck squamous cell carcinoma patients from a betel quid-prevalent region
- (2016) Jin-Ching Lin et al. Scientific Reports
- Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
- (2016) Hae Su Kim et al. Cancer Research and Treatment
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
- (2015) M. Vassilakopoulou et al. CLINICAL CANCER RESEARCH
- EBV Oncogene N-LMP1 Induces CD4 T Cell–Mediated Angiogenic Blockade in the Murine Tumor Model
- (2015) Tzong-Shoon Wu et al. JOURNAL OF IMMUNOLOGY
- Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
- (2015) Patcharee Ritprajak et al. ORAL ONCOLOGY
- Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas
- (2015) P. S. Hammerman et al. Cancer Discovery
- Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
- (2015) Mark Ayers et al. Journal for ImmunoTherapy of Cancer
- Risk of Cancer in Patients with Iron Deficiency Anemia: A Nationwide Population-Based Study
- (2015) Ning Hung et al. PLoS One
- Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
- (2014) A. Young et al. Cancer Discovery
- A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
- (2013) I. B. Barsoum et al. CANCER RESEARCH
- Iron in Infection and Immunity
- (2013) James E. Cassat et al. Cell Host & Microbe
- Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways
- (2013) Patrick L. Raber et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
- (2012) Monica Bernal et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes
- (2011) Michael S. Leibowitz et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
- (2011) Sebastian F. M. Häusler et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas
- (2011) Klaus Laimer et al. ORAL ONCOLOGY
- Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck
- (2010) Kazuaki Chikamatsu et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Spontaneous T cell responses to Epstein‐Barr virus‐encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy
- (2008) Debora Martorelli et al. INTERNATIONAL JOURNAL OF CANCER
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search